Getagraph.com logo
S&P 500
(0.01%) 5 188.22 points
Dow Jones
(0.43%) 39 053 points
Nasdaq
(-0.19%) 16 302 points
Oil
(1.05%) $79.20
Gas
(-0.95%) $2.19
Gold
(-0.23%) $2 318.80
Silver
(0.08%) $27.57
Platinum
(-0.31%) $985.35
USD/EUR
(0.14%) $0.931
USD/NOK
(0.10%) $10.91
USD/GBP
(0.12%) $0.800
USD/RUB
(0.20%) $91.63

リアルタイムの更新： Ind-Swift Laboratories [INDSWFTLAB.NS]

取引所: NSE セクター: Healthcare 産業: Drug Manufacturers—Specialty & Generic
Upcoming Earnings Alert

5 days till quarter result
(bmo 2024-05-13)

Expected move: +/- 6.26%

最終更新日時8 5月 2024 @ 19:00
25% discount on Stockinvest.us - Use code: Podcast

-0.64% INR 109.50

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 19:00):

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms...

Stats
本日の出来高 251 156
平均出来高 1.02M
時価総額 6.47B
EPS INR0 ( 2024-02-12 )
次の収益日 ( INR0 ) 2024-05-13
Last Dividend INR1.000 ( 2011-09-20 )
Next Dividend INR0 ( N/A )
P/E 14.90
ATR14 INR0.167 (0.15%)

ボリューム 相関

長: 0.11 (neutral)
短: 0.80 (strong)
Signal:(47.412) Same movement expected

Ind-Swift Laboratories 相関

10 最も正の相関
PVP.NS0.827
ICICIPHARM.NS0.813
KIMS.NS0.811
10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Ind-Swift Laboratories 相関 - 通貨/商品

The country flag -0.29
( neutral )
The country flag -0.48
( neutral )
The country flag 0.00
( neutral )
The country flag -0.48
( neutral )
The country flag -0.65
( moderate negative )
The country flag 0.54
( weak )

Ind-Swift Laboratories 財務諸表

Annual 2022
収益: INR12.07B
総利益: INR5.52B (45.70 %)
EPS: INR8.06
FY 2022
収益: INR12.07B
総利益: INR5.52B (45.70 %)
EPS: INR8.06
FY 2022
収益: INR10.39B
総利益: INR4.28B (41.20 %)
EPS: INR-0.360
FY 2021
収益: INR8.91B
総利益: INR3.61B (40.51 %)
EPS: INR-0.530

Financial Reports:

No articles found.

Ind-Swift Laboratories Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A) 		INR0
(N/A)

Ind-Swift Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.760 - low (50.00%) | Divividend Growth Potential Score: 2.47 - No dividend growth expected in the near future
Information
First Dividend INR1.000 2004-09-23
Last Dividend INR1.000 2011-09-20
Next Dividend INR0 N/A
Payout Date 2011-10-26
Next Payout Date N/A
# dividends 8 --
Total Paid Out INR9.00 --
Avg. Dividend % Per Year 0.00% --
Score 1.21 --
Div. Sustainability Score 1.760
Div.Growth Potential Score 2.47
Div. Directional Score 2.11 --
Next Divdend (Est)
 (2024-06-27)
INR0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
1.21
Pay Frequency
Annually
Yearly Payout
Year Amount Yield
2004 INR0 0.00%
2005 INR0 0.00%
2006 INR0 0.00%
2007 INR0 0.00%
2008 INR0 0.00%
2009 INR0 0.00%
2010 INR0 0.00%
2011 INR0 0.00%
2012 INR0 0.00%
2013 INR0 0.00%
2014 INR0 0.00%
2015 INR0 0.00%
2016 INR0 0.00%
2017 INR0 0.00%
2018 INR0 0.00%
2019 INR0 0.00%
2020 INR0 0.00%
2021 INR0 0.00%
2022 INR0 0.00%
2023 INR0 0.00%
2024 INR0 0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
TINPLATE.NS Dividend Junior 2023-08-11 Annually 19 0.72%
PDMJEPAPER.NS Dividend Junior 2023-08-03 Annually 9 0.65%
J&KBANK.NS Dividend Junior 2023-08-17 Sporadic 22 0.47%
DATAMATICS.NS Dividend Junior 2023-09-22 Annually 21 0.49%
SHYAMMETL.NS Dividend Junior 2023-06-05 Semi-Annually 4 0.70%
MAXHEALTH.NS Dividend Junior 2023-09-08 Insufficient data to determine frequency 2 0.07%
GSPL.NS Dividend Junior 2023-09-01 Annually 19 0.81%
BANKINDIA.NS Dividend Junior 2023-06-20 Sporadic 23 1.34%
PRAJIND.NS Dividend Junior 2023-07-19 Annually 22 0.83%
KABRAEXTRU.NS Dividend Junior 2023-07-13 Annually 23 0.83%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.03621.5009.2810.00[0 - 0.5]
returnOnAssetsTTM01.20000[0 - 0.3]
returnOnEquityTTM0.06121.500-0.431-0.647[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM00.800-5.00-4.00[1 - 3]
quickRatioTTM00.800-4.71-3.76[0.8 - 2.5]
cashRatioTTM01.500-1.111-1.667[0.2 - 2]
debtRatioTTM0-1.50000[0 - 0.6]
interestCoverageTTM2.561.000-0.163-0.163[3 - 30]
operatingCashFlowPerShareTTM16.902.004.378.74[0 - 30]
freeCashFlowPerShareTTM16.902.001.5523.10[0 - 20]
debtEquityRatioTTM0-1.50000[0 - 2.5]
grossProfitMarginTTM0.4761.0005.405.40[0.2 - 0.8]
operatingProfitMarginTTM0.1811.0008.378.37[0.1 - 0.6]
cashFlowToDebtRatioTTM01.000-1.111-1.111[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score1.760

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM15.191.0008.570[1 - 100]
returnOnEquityTTM0.06122.50-0.277-0.647[0.1 - 1.5]
freeCashFlowPerShareTTM16.902.004.373.10[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM16.902.004.378.74[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.4741.500-0.1760[0.5 - 2]
operatingCashFlowSalesRatioTTM0.08381.000-0.4060[0.1 - 0.5]
Total Score2.47

Ind-Swift Laboratories

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。